GGrantIndex
← Search

Development of Novel Antimicrobial Resistance Agents

$5,160,457N01FY2011AINIH

Achaogen, Inc., South San Francisco CA

Investigators

Abstract

This contract supports the advanced development of a novel antibacterial for the treatment of Gram-negative pathogens. The scope of work for this contract includes discovery, preclinical/non-clinical development activities, IND-enabling activities, and Phase I clinical trials.

View original record on NIH RePORTER →